User:Npalan5622
Nallasivam Palanisamy
Nallasivam Palanisamy is a cancer Research Scientist working as an Associate Scientist in the Department of Urology at the Henry Ford Health System, Detroit, MI, USA. He is also an Adjunct Associate Professor in the Department of Pathology, University of Michigan, Ann Arbor, Mi, USA.
Nallasivam Palanisamy attended University of Madras, Chennai, India for his undergraduate (BSc), Masters (MSc), MPhil and PhD.
Research Activity:Cite error: There are <ref> tags on this page without content in them (see the help page).
Nallasivam Palanisamy's research interests are on the discovery and characterization of gene fusions in cancer and understand their role in carcinogenesis from a translational research perspective. Using genomic technologies such as high-density array comparative genomic hybridization, advanced molecular cytogenetic technologies including FISH, CGH, spectral karyotyping, gene expression microarrays, and next generation sequencing technology, his laboratory investigates the transcriptional and genomic architectures of solid cancer genome. In-depth analysis of genomic amplifications provided an unprecedented view and identified rare gene fusions formed at the boundaries of amplification and deletions. He pioneered on the application of next generation sequencing technology for the discovery of new recurrent gene fusions in cancer. The primary goal of this approach is to identify novel gene fusions specific for each cancer type. Further, he is interested in applying the newly developed target capture of all human exons and resequencing approach to find disease causing gene mutations. In his research work, employing the next generation sequencing approach with emphasis on RNAseq provided a unique opportunity to interrogate the cancer transcriptome in an unbiased manner to identify novel gene fusions, alternative transcripts, non-coding RNA, SNP’s, micro-RNA and expressed pseudogenes not detectable by gene expression microarray analysis. Recently, he discovered a new recurrent gene fusion in a subset of ETS negative prostate cancer. His long-term research goals are to conduct advanced research applying the next generation sequencing technology for an integrated analysis using data from RNA and DNA processing, genotyping, chip sequence, gene expression, copy number analysis for variations and rearrangements and methylation analysis to understand the genetic complexity of cancer genome in a comprehensive manner. This work will lead to the identification of novel cancer biomarkers for routine diagnosis and treatment follow up.
Research Publications:
1. Lakshminarayana P, Nallasivam P (Palanisamy N). Cornelia de Lange syndrome with ring chromosome 3. J Med Genet. 1990 Jun;27(6):405-6. PubMed PMID: 2359108; PubMed Central PMCID: PMC1017144.
2. Aikawa M, Sivam PN (Palanisamy N), Kuro-o M, Kimura K, Nakahara K, Takewaki S, Ueda M, Yamaguchi H, Yazaki Y, Periasamy M. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 1993 Dec;73(6):1000-12. PubMed PMID: 7916668.
3. Iida S, Rao PH, Nallasivam P (Palanisamy N), Hibshoosh H, Butler M, Louie DC, Dyomin V, Ohno H, Chaganti RS, Dalla-Favera R. The t (9;14) (p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 1996 Dec 1;88(11):4110-7. PubMed PMID: 8943844.
4. Selvakumar A, Steffens U, Palanisamy N, Chaganti RS, Dupont B. Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103. Tissue Antigens. 1997 Jun;49(6):564-73. PubMed PMID: 9234477.
5. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab. 1998 May;83(5):1766-70. doi: 10.1210/jcem.83.5.4806. PubMed PMID: 9589690.
6. Rao PH, Houldsworth J, Palanisamy N, Murty VV, Reuter VE, Motzer RJ, Bosl GJ, Chaganti RS. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998 Oct 1;58(19):4260-3. PubMed PMID: 9766648.
7. Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE. A common molecular basis for rearrangement disorders on chromosome 22q11. Hum Mol Genet. 1999 Jul;8(7):1157-67. PubMed PMID: 10369860.
8. Brown SB, Brierley TT, Palanisamy N, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Pike JW, Arnold A. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab. 2000 Feb;85(2):868-72. doi: 10.1210/ jcem.85.2.6426. PubMed PMID: 10690903.
9. Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J, Chaganti RS. MUC1 is activated in a B-cell lymphoma by the t (1;14) (q21; q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood. 2000 Apr 15;95(8):2666-71. PubMed PMID: 10753849.
10. Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001 Mar;14(3):277-89. PubMed PMID: 11290337.
11. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Houldsworth J, Chaganti RS. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene. 2001 Nov 15;20(52):7686-93. doi: 10.1038/sj.onc.1204989. PubMed PMID: 11753646.
12. Costa J, Shattuck TM, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM, Wierman ME, Hollenberg A, Tojo K, Chaganti RSK, Arnold A. Mutational analyses of connexin 26 connexin 30 and connexin 46 as candidate tumor suppressor genes in parathyroid carcinoma. J Endocr Genet. 2002; 3:57-62. doi: DOI: 10.1515/ IJDHD.2002.3.2.57.
13. Palanisamy N, Abou-Elella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, Terayu-Feldstein J, Cigudosa JC, Rao PH, Sanger WG, Weisenburger DD, Chaganti RS. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes Cancer. 2002 Feb;33(2):114-22. PubMed PMID: 11793437.
14. Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Arnold A. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol. 2002 Jun;13(6):1490-8. PubMed PMID: 12039978.
15. Butler MP, Iida S, Capello D, Rossi D, Rao PH, Nallasivam P, Louie DC, Chaganti S, Au T, Gascoyne RD, Gaidano G, Chaganti RS, Dalla-Favera R. Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. Cancer Res. 2002 Jul 15;62(14):4089-94. PubMed PMID: 12124346.
16. Dyomin VG, Chaganti SR, Dyomina K, Palanisamy N, Murty VV, Dalla-Favera R, Chaganti RS. BCL8 is a novel, evolutionarily conserved human gene family encoding proteins with presumptive protein kinase A anchoring function. Genomics. 2002 Aug;80(2):158-65. PubMed PMID: 12160729.
17. Shattuck TM, Kim TS, Costa J, Yandell DW, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM, Wierman ME, Hollenberg A, Tojo K, Chaganti RS, Arnold A. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf). 2003 Aug;59(2):180-9. PubMed PMID: 12864795.
18. Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen Y, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chaganti RS. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2004 Mar 1;103(5):1862-8. doi: 10.1182/blood-2003-04-1359. Epub 2003 Nov 13. PubMed PMID: 14615382.
19. Schmidt HH, Dyomin VG, Palanisamy N, Itoyama T, Nanjangud G, Pirc-Danoewinata H, Haas OA, Chaganti RS. Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t (12;14) (q23;q32). Oncogene. 2004 Sep 9;23(41):6991-6. doi: 10.1038/sj.onc. 1207934. PubMed PMID: 15273723.
20. Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol. 2005 Apr;166(4):1229-38. doi: 10.1016/S0002-9440(10) 62341-3. PubMed PMID: 15793301; PubMed Central PMCID: PMC1602397.
21. Lian Q, Lye E, Suan Yeo K, Khia Way Tan E, Salto-Tellez M, Liu TM, Palanisamy N, El Oakley RM, Lee EH, Lim B, Lim SK. Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells. 2007 Feb;25(2):425-36. doi: 10.1634/stemcells. 2006-0420. Epub 2006 Oct 19. PubMed PMID: 17053208.
22. Chen W, Salto-Tellez M, Palanisamy N, Ganesan K, Hou Q, Tan LK, Sii LH, Ito K, Tan B, Wu J, Tay A, Tan KC, Ang E, Tan BK, Tan PH, Ito Y, Tan P. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes Cancer. 2007 Mar;46(3):288-301. doi: 10.1002/gcc. 20411. PubMed PMID: 17171680.
23. Zeng J, Du J, Zhao Y, Palanisamy N, Wang S. Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells. 2007 Apr;25(4):1055-61. doi: 10.1634/stemcells.2006-0616. PubMed PMID: 17420229.
24. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet. 2007 Jun;3(6): e87. doi: 10.1371/journal.pgen.0030087. Epub 2007 Apr 17. PubMed PMID: 17542648; PubMed Central PMCID: PMC1885282.
25. Ruan Y, Ooi HS, Choo SW, Chiu KP, Zhao XD, Srinivasan KG, Yao F, Choo CY, Liu J, Ariyaratne P, Bin WG, Kuznetsov VA, Shahab A, Sung WK, Bourque G, Palanisamy N, Wei CL. Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res. 2007 Jun;17(6):828-38. doi: 10.1101/gr.6018607. PubMed PMID: 17568001; PubMed Central PMCID: PMC1891342.
26. Legrand, Chang, Ong, Neo, Palanisamy N. Automated identification of chromosome segments involved in translocations by combining spectral karyotyping and banding analysis. IEEE Transactions on Systems, Man & Cybernetics (Part A Systems & Humans). 2008; 38(6):1374-1384. doi: DOI:10.1109/TSMCA.2008.2003963.
27. Legrand, Chang, Ong, Neo, Palanisamy N. Chromosome Classification Using Dynamic Time Warping. Pattern Recognition Letters. 2008; 29:215-222. doi: doi: 10.1016/j.patrec.2007.09.017. 28. Huynh H, Chow PK, Palanisamy N, Salto-Tellez M, Goh BC, Lee CK, Somani A, Lee HS, Kalpana R, Yu K, Tan PH, Wu J, Soong R, Lee MH, Hor H, Soo KC, Toh HC, Tan P. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 2008 Jul;49(1): 52-60. doi: 10.1016/j. jhep. 2008.02.022. Epub 2008 Apr 28. PubMed PMID: 18490075.
29. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008 Sep 15;68(18):7629-37. doi: 10.1158/0008-5472.CAN-08-2014. PubMed PMID: 18794152; PubMed Central PMCID: PMC2760292.
30. Poonepalli A, Banerjee B, Ramnarayanan K, Palanisamy N, Putti TC, Hande MP. Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer. Genes Chromosomes Cancer. 2008 Dec;47(12):1098-109. doi: 10.1002/gcc.20608. PubMed PMID: 18720522.
31. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008 Dec 12;322(5908):1695-9. doi: 10.1126/science.1165395. Epub 2008 Nov 13. PubMed PMID: 19008416; PubMed Central PMCID: PMC2684823.
32. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009 Mar 5;458(7234):97-101. doi: 10.1038/nature07638. Epub 2009 Jan 11. PubMed PMID: 19136943; PubMed Central PMCID: PMC2725402.
33. Vega VB, Cheung E, Palanisamy N, Sung WK. Inherent signals in sequencing-based Chromatin-ImmunoPrecipitation control libraries. PLoS One. 2009;4(4): e5241. doi: 10.1371/journal.pone.0005241. Epub 2009 Apr 15. PubMed PMID: 19367334; PubMed Central PMCID: PMC2666154.
34. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, Lonigro RJ, Schroth G, Kumar-Sinha C, Chinnaiyan AM. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12353-8. doi: 10.1073/pnas.0904720106. Epub 2009 Jul 10. PubMed PMID: 19592507; PubMed Central PMCID: PMC2708976.
35. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009 Aug;22(8):1083-93. doi: 10.1038/modpathol. 2009.69. Epub 2009 May 1. PubMed PMID: 19407851; PubMed Central PMCID: PMC2760294.
36. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, Liu ET, Karuturi KM, Lim B, Miller LD. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009 Aug;119(8):2171-83. doi: 10.1172/ JCI37622. Epub 2009 Jul 20. PubMed PMID: 19620787; PubMed Central PMCID: PMC2719918.
37. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009 Sep;22(9):1176-85. doi: 10.1038/modpathol.2009.79. Epub 2009 May 22. PubMed PMID: 19465903; PubMed Central PMCID: PMC2760291.
38. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol. 2009 Nov;27(11):1005-11. doi: 10.1038/nbt.1584. Epub 2009 Nov 1. PubMed PMID: 19881495; PubMed Central PMCID: PMC3086882.
39. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009 Nov 27;326(5957):1230. doi: 10.1126/science.1178124. Epub 2009 Oct 29. PubMed PMID: 19933109; PubMed Central PMCID: PMC2935583.
40. Chinnaiyan AM, Palanisamy N. Chromosomal aberrations in solid tumors. Prog Mol Biol Transl Sci. 2010; 95:55-94. doi: 10.1016/B978-0-12-385071-3.00004-6. Review. PubMed PMID: 21075329.
41. Palanisamy N. Chromosomal translocations in AML: detection and prognostic significance. Cancer Treat Res. 2010; 145:41-58. doi: 10.1007/978-0-387-69259-3_3. Review. PubMed PMID: 20306244.
42. Chandra, Cyril, Lakshminarayana, Nallasivam P, Ramesh, Gopinath, Marimuthu. Cytogenetic Evaluation of Down syndrome: A Review of 1020 Referral Cases. Int J Hum Genet. 2010; 10(1-3):87-93. doi: ISSN: 0972-3757 WOS:000278231800013.
43. Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2010 Apr;34(4):478-85. doi: 10.1097/PAS.0b013e3181d6827b. PubMed PMID: 20220513.
44. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010 Jul;16(7):793-8. doi: 10.1038/nm. 2166. Epub 2010 Jun 6. PubMed PMID: 20526349; PubMed Central PMCID: PMC2903732.
45. Yu J, Cao Q, Yu J, Wu L, Dallol A, Li J, Chen G, Grasso C, Cao X, Lonigro RJ, Varambally S, Mehra R, Palanisamy N, Wu JY, Latif F, Chinnaiyan AM. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene. 2010 Sep 30;29(39):5370-80. doi: 10.1038/onc.2010.269. Epub 2010 Jul 12. PubMed PMID: 20622896; PubMed Central PMCID: PMC2948081.
46. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, Ittmann M. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res. 2011 Feb 15;71(4):1325-33. doi: 10.1158/0008-5472.CAN-10-2210. Epub 2010 Dec 17. PubMed PMID: 21169414; PubMed Central PMCID: PMC3041849.
47. Tao J, Deng NT, Ramnarayanan K, Huang B, Oh HK, Leong SH, Lim SS, Tan IB, Ooi CH, Wu J, Lee M, Zhang S, Rha SY, Chung HC, Smoot DT, Ashktorab H, Kon OL, Cacheux V, Yap C, Palanisamy N, Tan P. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 2011 Apr 6;3(77):77ra30. doi: 10.1126/scitranslmed. 3001423. PubMed PMID: 21471434.
48. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, Palanisamy N, Voorhoeve PM, Tan P. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011 May 1;17(9):2657-67. doi: 10.1158/1078-0432.CCR-10-3152. Epub 2011 Mar 17. PubMed PMID: 21415212.
49. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010. PubMed PMID: 21575865; PubMed Central PMCID: PMC3113473.
50. Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, Wang R, Fries DF, Han B, Asangani IA, Cao X, Li Y, Omenn GS, Pflueger D, Gopalan A, Reuter VE, Kahoud ER, Cantley LC, Rubin MA, Palanisamy N, Varambally S, Chinnaiyan AM. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov. 2011 Jun;1(1):35-43. doi: 10.1158/2159-8274.CD-10-0022. Epub 2011 Jun 1. PubMed PMID: 22140652; PubMed Central PMCID: PMC3227139.
51. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011 Jul;21(7):1028-41. doi: 10.1101/gr.119347.110. PubMed PMID: 21724842; PubMed Central PMCID: PMC3129246.
52. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, Iyer HK, Palanisamy N, Maher CA, Chinnaiyan AM. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011 Jul 31;29(8):742-9. doi: 10.1038/ nbt.1914. PubMed PMID: 21804560; PubMed Central PMCID: PMC3152676.
53. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/ scitranslmed. 3001970. PubMed PMID: 21813756; PubMed Central PMCID: PMC3245713.
54. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, Wu YM, Tomlins SA, Palanisamy N, Qin Z, Yu J, Maher CA, Varambally S, Chinnaiyan AM. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011 Aug 16;20(2):187-99. doi: 10.1016/j.ccr.2011.06.016. PubMed PMID: 21840484; PubMed Central PMCID: PMC3157014.
55. Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart RC, Tomlins S, Bradford C, Carey T, Wolf G, Kalyana-Sundaram S, Chinnaiyan AM, Varambally S, D'Silva NJ. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene. 2011 Oct 20;30(42):4339-49. doi: 10.1038/onc.2011.141. Epub 2011 May 2. PubMed PMID: 21532618; PubMed Central PMCID: PMC3154567.
56. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion, and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. 2011 Nov;32 (11):1607-14. doi:10.1093/ carcin/ bgr184. Epub 2011 Aug 8. PubMed PMID: 21828058; PubMed Central PMCID: PMC3204346.
57. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011 Nov 20;17(12):1646-51. doi: 10.1038/nm.2580. PubMed PMID: 22101766; PubMed Central PMCID: PMC3233654.
58. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, Asangani IA, Kothari V, Prensner JR, Lonigro RJ, Iyer MK, Barrette T, Shanmugam A, Dhanasekaran SM, Palanisamy N, Chinnaiyan AM. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell. 2012 Jun 22;149(7): 1622-34. doi: 10.1016/j.cell.2012. 04.041. PubMed PMID: 22726445; PubMed Central PMCID: PMC3597446.
59. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125. PubMed PMID: 22722839; PubMed Central PMCID: PMC3396711.
60. Kalyana-Sundaram S, Shankar S, Deroo S, Iyer MK, Palanisamy N, Chinnaiyan AM, Kumar-Sinha C. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia. 2012 Aug;14(8):702-8. PubMed PMID: 22952423; PubMed Central PMCID: PMC3431177.
61. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012 Aug;136(8):935-46. doi: 10.5858/arpa.2011-0424-OA. PubMed PMID: 22849743; PubMed Central PMCID: PMC3667408.
62. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Chinnaiyan AM. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012 Sep;3(9):1011-25. doi: 10.18632/oncotarget.622. PubMed PMID: 22948084; PubMed Central PMCID: PMC3663613. Shared Senior Authorship
63. Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia. 2012 Oct;14(10):905-14. PubMed PMID: 23097625; PubMed Central PMCID: PMC3479836.
64. Young A, Palanisamy N, Siddiqui J, Wood DP, Wei JT, Chinnaiyan AM, Kunju LP, Tomlins SA. Correlation of urine TMPRSS2: ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol. 2012 Nov;138(5):685-96. doi: 10.1309/AJCPU7PPWUPYG8OH. PubMed PMID: 23086769; PubMed Central PMCID: PMC3597433.
65. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2013 Jan 10;49(1):80-93. doi: 10.1016/j.molcel.2012.10.008. Epub 2012 Nov 15. PubMed PMID: 23159737; PubMed Central PMCID: PMC3547524.
66. Velusamy T, Palanisamy N, Kalyana-Sundaram S, Sahasrabuddhe AA, Maher CA, Robinson DR, Bahler DW, Cornell TT, Wilson TE, Lim MS, Chinnaiyan AM, Elenitoba-Johnson KS. Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3035-40. doi: 10.1073/pnas.1214326110. Epub 2013 Feb 4. PubMed PMID: 23382248; PubMed Central PMCID: PMC3581970.
67. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013 Mar 1;73(5):1635-46. doi: 10.1158/0008-5472.CAN-12-3349. Epub 2013 Feb 26. PubMed PMID: 23442322; PubMed Central PMCID: PMC3600586.
68. Tomlins SA, Palanisamy N, Brenner JC, Stall JN, Siddiqui J, Thomas DG, Lucas DR, Chinnaiyan AM, Kunju LP. Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol. 2013 Jun;139(6):771-9. doi: 10.1309/AJCPN4L1BMRQPEIT. PubMed PMID: 23690120; PubMed Central PMCID: PMC3662488.
69. Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Mosquera JM, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013 Jun;26(6):835-48. doi: 10.1038/modpathol.2012.234. Epub 2013 Jan 25. PubMed PMID: 23348902; PubMed Central PMCID: PMC3672354.
70. Mehra R, Dhanasekaran SM, Palanisamy N, Vats P, Cao X, Kim JH, Kim DS, Johnson T, Fullen DR, Chinnaiyan AM. Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence in Situ Hybridization Reveals Recurrent ETV1 Amplification. Transl Oncol. 2013 Aug;6(4):405-12. Print 2013 Aug. PubMed PMID: 23908683; PubMed Central PMCID: PMC3730015.
71. Costa-Guda J, Imanishi Y, Palanisamy N, Kawamata N, Phillip Koeffler H, Chaganti RS, Arnold A. Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine. 2013 Oct;44(2): 489-95. doi: 10.1007/s12020-013-9903-4. Epub 2013 Feb 24. PubMed PMID: 23435613; PubMed Central PMCID: PMC3683451.
72. Warrick JI, Tomlins SA, Carskadon SL, Young AM, Siddiqui J, Wei JT, Chinnaiyan AM, Kunju LP, Palanisamy N. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol. 2014 Apr;27(4):609-20. doi: 10.1038/modpathol.2013.169. Epub 2013 Sep 27. PubMed PMID: 24072184; PubMed Central PMCID: PMC3968238.
73. Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, Kunju LP, Cooney KA, Tomlins SA. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol. 2014 May;38(5):615-26. doi: 10.1097/PAS.0000000000000090. PubMed PMID: 24722062; PubMed Central PMCID: PMC3988475. First Authors with Equal Contribution
74. Harms PW, Hristov AC, Kim DS, Anens T, Quist MJ, Siddiqui J, Carskadon S, Mehra R, Fullen DR, Johnson TM, Chinnaiyan AM, Palanisamy N. Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. Human Pathology-Case Reports. 2014 June; 1(2):21-28. doi: DOI:10.1016/ j. ehpc.2014.07.
75. Zuhlke KA, Johnson AM, Tomlins SA, Palanisamy N, Carpten JD, Lange EM, Isaacs WB, Cooney KA. Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. Prostate. 2014 Jun;74(9):983-90. doi: 10.1002/pros.22818. Epub 2014 May 6. PubMed PMID: 24796539; PubMed Central PMCID: PMC4230298.
76. Smith SC, Palanisamy N, Betz BL, Tomlins SA, Mehra R, Schmidt LA, Lucas DR, Myers JL. At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases. Histopathology. 2014 Jul;65(1):144-6. doi: 10.1111/his.12354. Epub 2014 Mar 14. PubMed PMID: 24372335. First Authors with Equal Contribution
77. Palanisamy N. Hopes and pitfalls in prostate cancer diagnostics and therapeutics. Journal of Rashid Latif Medical College. 2014 July-Dec; 3(2).
78. Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014 Jul 31; 5:4527. doi: 10.1038/ncomms5527. PubMed PMID: 25078033; PubMed Central PMCID: PMC4130352.
79. Chakravarthi BV, Pathi SS, Goswami MT, Cieślik M, Zheng H, Nallasivam S, Arekapudi SR, Jing X, Siddiqui J, Athanikar J, Carskadon SL, Lonigro RJ, Kunju LP, Chinnaiyan AM, Palanisamy N, Varambally S. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget. 2014 Aug 30;5(16): 6654-69. doi: 10.18632/ oncotarget.2208. PubMed PMID: 25115393; PubMed Central PMCID: PMC4196154.
80. Kunju LP, Carskadon S, Siddiqui J, Tomlins SA, Chinnaiyan AM, Palanisamy N. Novel RNA hybridization method for the in-situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol. 2014 Sep;22(8): e32-40. doi: 10.1097/PAI.0000000000000095. PubMed PMID: 25203299; PubMed Central PMCID: PMC4159774.
81. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 3;6(252):252ra122. doi: 10.1126/scitranslmed.3009332. PubMed PMID: 25186177; PubMed Central PMCID: PMC4407499.
82. Pletneva MA, Andea A, Palanisamy N, Betz BL, Carskadon S, Wang M, Patel RM, Fullen DR, Harms PW. Clear cell melanoma: a cutaneous clear cell malignancy. Arch Pathol Lab Med. 2014 Oct;138(10):1328-36. doi: 10.5858/arpa.2014-0307-CC. Review. PubMed PMID: 25268196.
83. Ha Lan TT, Chen SJ, Arps DP, Fullen DR, Patel RM, Siddiqui J, Carskadon S, Palanisamy N, Harms PW. Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma. J Cutan Pathol. 2014 Nov;41(11):831-8. doi: 10.1111/cup.12387. Epub 2014 Nov 3. PubMed PMID: 25263756.
84. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014 Nov 21; 5:5383. doi: 10.1038/ncomms6383. PubMed PMID: 25415230; PubMed Central PMCID: PMC4241506.
85. Fisher CA, Harms PW, McHugh JB, Edwards PC, Siddiqui J, Palanisamy N, Bichakjian CK, Benavides E, Danciu TE. Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Dec;118(6):703-12. doi: 10.1016/j.oooo.2014.09.012. Epub 2014 Sep 17. PubMed PMID: 25457888.
86. Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014 Dec 22; 5:5893. doi: 10.1038/ncomms6893. PubMed PMID: 25531467; PubMed Central PMCID: PMC4274748.
87. Palanisamy N, Tsodikov A, Yan W, Suleman K, Rittmaster R, Lucia SM, Chinnaiyan AM, Fleshner N, Kunju LP. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial. Urol Oncol. 2015 Mar;33(3): 108.e5-13. doi: 10.1016/j.urolonc.2014.07.015. Epub 2014 Aug 28. PubMed PMID: 25175425.
88. Malik R, Khan AP, Asangani IA, Cieślik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015 Apr;21(4):344-52. doi: 10.1038/nm.3830. Epub 2015 Mar 30. PubMed PMID: 25822367; PubMed Central PMCID: PMC4390530.
89. Sathyanarayana UG, Birch C, Nagle RB, Tomlins SA, Palanisamy N, Zhang W, Hubbard A, Brunhoeber P, Wang Y, Tang L. Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis. Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):364-73. doi: 10.1097/PAI.0000000000000085. PubMed PMID: 25265431.
90. Harms PW, Fullen DR, Patel RM, Chang D, Shalin SC, Ma L, Wood B, Beer TW, Siddiqui J, Carskadon S, Wang M, Palanisamy N, Fisher GJ, Andea A. Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses. Hum Pathol. 2015 May;46(5):690-7. doi: 10.1016/ j. humpath. 2015.01. 006. Epub 2015 Jan 14. PubMed PMID: 25704628.
91. Demicco EG, Harms PW, Patel RM, Smith SC, Ingram D, Torres K, Carskadon SL, Camelo-Piragua S, McHugh JB, Siddiqui J, Palanisamy N, Lucas DR, Lazar AJ, Wang WL. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015 May;143(5):672-82. doi: 10.1309/ AJCPN25NJTOUNPNF. PubMed PMID: 25873501; PubMed Central PMCID: PMC4505928.
92. Higgins J, Brogley M, Palanisamy N, Mehra R, Ittmann MM, Li JZ, Tomlins SA, Robins DM. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer. 2015 Jun;6(2-3):67-86. doi: 10.1007/s12672-014-0215-9. Epub 2015 Jan 29. PubMed PMID: 25631336; PubMed Central PMCID: PMC4414739.
93. Bollig-Fischer A, Michelhaugh SK, Wijesinghe P, Dyson G, Kruger A, Palanisamy N, Choi L, Alosh B, Ali-Fehmi R, Mittal S. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget. 2015 Jun 10;6(16):14614-24. doi: 10.18632/oncotarget.3786. PubMed PMID: 25970776; PubMed Central PMCID: PMC4546491.
94. Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. Prostate. 2015 Jul 1;75(10):1051-62. doi: 10.1002/pros.22989. Epub 2015 Mar 23. PubMed PMID: 25809148; PubMed Central PMCID: PMC4832366.
95. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080. PubMed PMID: 26325560; PubMed Central PMCID: PMC4758114.
96. Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu YM, Dhanasekaran SM, Palanisamy N, Siddiqui J, Cao X, Su F, Wang R, Xiao H, Kunju LP, Mehra R, Tomlins SA, Fullen DR, Bichakjian CK, Johnson TM, Dlugosz AA, Chinnaiyan AM. The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Res. 2015 Sep 15;75(18):3720-3727. doi: 10.1158/0008-5472. CAN-15-0702. Epub 2015 Aug 3. PubMed PMID: 26238782; PubMed Central PMCID: PMC4573907.
97. Goswami MT, Chen G, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015 Sep 15;6(27):23445-61. doi: 10.18632/oncotarget.4352. PubMed PMID: 26140362; PubMed Central PMCID: PMC4695129.
98. Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JM, Tomlins SA. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Mod Pathol. 2016 Feb;29(2):157-65. doi: 10.1038/ modpathol. 2015.148. Epub 2016 Jan 8. PubMed PMID: 26743468; PubMed Central PMCID: PMC4732921.
99. McDaniel AS, Palanisamy N, Smith SC, Robinson DR, Wu YM, Chinnaiyan AM, McHugh JB, Greenson JK, Kunju LP. A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. Histol Histopathol. 2016 Feb;31(2):223-30. doi: 10.14670/HH-11-670. Epub 2015 Sep 26. PubMed PMID: 26404914.
100. Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ. Corrigendum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2016 Feb 24; 7:10726. doi: 10.1038/ncomms10726. PubMed PMID: 26908012; PubMed Central PMCID: PMC4770070.
101. Tillman BN, Yanik M, Birkeland AC, Liu CJ, Hovelson DH, Cani AK, Palanisamy N, Carskadon S, Carey TE, Bradford CR, Tomlins SA, McHugh JB, Spector ME, Brenner JCh. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. Head Neck. 2016 Apr;38 Suppl 1: E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5. PubMed PMID: 26849095; PubMed Central PMCID: PMC4844767.
102. Huang KC, Bégin LR, Palanisamy N, Donnelly B, Bismar TA. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. Urol Oncol. 2016 May;34(5): 235.e1-10. doi: 10.1016/j.urolonc.2015.11.015. Epub 2015 Dec 22. PubMed PMID: 26725250.
103. Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, Burness ML, Azizi E, Simeone DM, Wicha MS, Kim J, Nagrath S. Tunable Thermal-Sensitive Polymer-Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor Cells. Adv Mater. 2016 Jun;28(24):4891-7. doi: 10.1002/adma. 201600658. Epub 2016 Apr 26. PubMed PMID: 27115557; PubMed Central PMCID: PMC 5680542.
104. Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey D, Diehl JA, Palanisamy V. RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genet. 2016 Sep;12(9):e1006306. doi: 10.1371/journal.pgen.1006306. eCollection 2016 Sep. PubMed PMID: 27606879; PubMed Central PMCID: PMC5015924.
105. East E, Fullen DR, Arps D, Patel RM, Palanisamy N, Carskadon S, Harms PW. Morpheaform basal cell carcinomas with areas of single-cell pattern of infiltration: diagnostic utility of p63 and cytokeratin. Am J Dermatopathol. 2016 Oct;38(10):744-50. doi: 10.1097/DAD.0000000000000541. PubMed PMID: 27043336.
106. Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol. 2016 Oct;3(4):240-253. doi: 10.1016/j.ajur.2016.08.005. Epub 2016 Aug 25. Review. PubMed PMID: 29264192; PubMed Central PMCID: PMC5730836.
107. Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey D, Diehl JA, Palanisamy V. Correction: RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genet. 2016 Oct;12(10): e1006411. doi: 10.1371/journal.pgen.1006411. eCollection 2016 Oct. PubMed PMID: 27783624; PubMed Central PMCID: PMC5081202.
108. Harms PW, Hocker TL, Zhao L, Chan MP, Andea AA, Wang M, Harms KL, Wang ML, Carskadon S, Palanisamy N, Fullen DR. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. Hum Pathol. 2016 Dec; 58:152-160. doi: 10.1016/j.humpath.2016.07.029. Epub 2016 Aug 26. PubMed PMID: 27569296.
109. Mani RS, Amin MA, Li X, Kalyana-Sundaram S, Veeneman BA, Wang L, Ghosh A, Aslam A, Ramanand SG, Rabquer BJ, Kimura W, Tran M, Cao X, Roychowdhury S, Dhanasekaran SM, Palanisamy N, Sadek HA, Kapur P, Koch AE, Chinnaiyan AM. Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Rep. 2016 Dec 6;17(10):2620-2631. doi: 10.1016/j.celrep.2016.11.019. PubMed PMID: 27926866; PubMed Central PMCID: PMC5147555.
110. Chakravarthi BV, Goswami MT, Pathi SS, Robinson AD, Cieślik M, Chandrashekar DS, Agarwal S, Siddiqui J, Daignault S, Carskadon SL, Jing X, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S. MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene. 2016 Dec 8;35(49):6330-6340. doi: 10.1038/onc.2016.164. Epub 2016 Jun 6. PubMed PMID: 27270442; PubMed Central PMCID: PMC5140777.
111. Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunju LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KW, Keller E, Thomas D, Nagrath S, Morgan T, Day ML. HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Res. 2017 Jan 1;77(1):74-85. doi: 10.1158/0008-5472.CAN-16-1656. Epub 2016 Oct 28. PubMed PMID: 27793843; PubMed Central PMCID: PMC5214538.
112. Chakravarthi BV, Goswami MT, Pathi SS, Dodson M, Chandrashekar DS, Agarwal S, Nepal S, Hodigere Balasubramanya SA, Siddiqui J, Lonigro RJ, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S. Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. Prostate. 2017 Jan;77(1):10-21. doi: 10.1002/pros.23243. Epub 2016 Aug 22. PubMed PMID: 27550065.
113. Zhang Z, Shiratsuchi H, Palanisamy N, Nagrath S, Ramnath N. Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. J Thorac Oncol. 2017 Feb;12(2):397-402. doi: 10.1016/j.jtho.2016.07.027. Epub 2016 Aug 6. PubMed PMID: 27507192; PubMed Central PMCID: PMC5263096.
114. Williamson SR, Grignon DJ, Cheng L, Favazza L, Gondim DD, Carskadon S, Gupta NS, Chitale DA, Kalyana-Sundaram S, Palanisamy N. Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis? Am J Surg Pathol. 2017 Mar;41(3):287-298. doi: 10.1097/PAS.0000000000000776. PubMed PMID: 28009604.
115. Smith SC, Palanisamy N, Martin E, Almenara J, McHugh JB, Choi EK, Lucas DR, Betz BL, Thomas D, Patel RM. The utility of ETV1, ETV4 and ETV5 RNA in-situ hybridization in the diagnosis of CIC-DUX sarcomas. Histopathology. 2017 Mar;70(4):657-663. doi: 10.1111/his.13112. Epub 2016 Dec 16. PubMed PMID: 27790742. First Authors with Equal Contribution
116. Williamson SR, Eble JN, Palanisamy N. Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. Hum Pathol. 2017 Apr; 62:175-179. doi: 10.1016/j.humpath.2016.10.024. Epub 2016 Nov 15. PubMed PMID: 27864122.
117. Harms KL, Chubb H, Zhao L, Fullen DR, Bichakjian CK, Johnson TM, Carskadon S, Palanisamy N, Harms PW. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis. Hum Pathol. 2017 Sep; 67:78-84. doi: 10.1016/j.humpath.2017.07.009. Epub 2017 Jul 21. PubMed PMID: 28739498.
118. Murlidhar V, Reddy RM, Fouladdel S, Zhao L, Ishikawa MK, Grabauskiene S, Zhang Z, Lin J, Chang AC, Carrott P, Lynch WR, Orringer MB, Kumar-Sinha C, Palanisamy N, Beer DG, Wicha MS, Ramnath N, Azizi E, Nagrath S. Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. Cancer Res. 2017 Sep 15;77(18):5194-5206. doi: 10.1158/0008-5472.CAN-16-2072. Epub 2017 Jul 17. PubMed PMID: 28716896; PubMed Central PMCID: PMC5600850.
119. Wang L, Harms PW, Palanisamy N, Carskadon S, Cao X, Siddiqui J, Patel RM, Zelenka-Wang S, Durham AB, Fullen DR, Harms KL, Su F, Shukla S, Mehra R, Chinnaiyan AM. Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay. Clin Cancer Res. 2017 Sep 15;23(18):5622-5630. doi: 10.1158/1078-0432.CCR-17-0299. Epub 2017 Jun 12. PubMed PMID: 28606924; PubMed Central PMCID: PMC5600832.
120. Favazza L, Chitale DA, Barod R, Rogers CG, Kalyana-Sundaram S, Palanisamy N, Gupta NS, Williamson SR. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Mod Pathol. 2017 Nov;30(11):1603-1612. doi: 10.1038/modpathol.2017.72. Epub 2017 Jul 21. PubMed PMID: 28731045.
121. Smith SC, Gooding WE, Elkins M, Patel RM, Harms PW, McDaniel AS, Palanisamy N, Uram-Tuculescu C, Balzer BB, Lucas DR, Seethala RR, McHugh JB. Solitary Fibrous Tumors of the Head and Neck: A Multi-Institutional Clinicopathologic Study. Am J Surg Pathol. 2017 Dec;41(12):1642-1656. doi: 10.1097/ PAS.0000000000000940. PubMed PMID: 28877055; PubMed Central PMCID: PMC5680135.
122. Chakravarthi BVSK, Goswami MT, Pathi SS, Dodson M, Chandrashekar DS, Agarwal S, Nepal S, Hodigere Balasubramanya SA, Siddiqui J, Lonigro RJ, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S. Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer. Prostate. 2018 Jun;78(9):693-694. doi: 10.1002/pros.23533. Epub 2018 Apr 10. PubMed PMID: 29744932.
123. Kou R, Zhao J, Gogoi P, Carskadon S, Chow W, Hwang C, Palanisamy N, Leung C, Wang Y. Enrichment and mutation detection of circulating tumor cells from blood samples. Oncol Rep. 2018 Jun;39(6):2537-2544. doi: 10.3892/or.2018.6342. Epub 2018 Mar 30. PubMed PMID: 29620284; PubMed Central PMCID: PMC5983925.
124. Jebastin JAS, Smith SC, Perry KD, Gupta NS, Alanee S, Carskadon S, Chitale DA, Palanisamy N, Williamson SR. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements. Histopathology. 2018 Aug;73(2):321-326. doi: 10.1111/his.13526. Epub 2018 May 30. PubMed PMID: 29617048.
125. Stanoszek LM, Chan MP, Palanisamy N, Carskadon S, Siddiqui J, Patel RM, Harms KL, Lowe L, Fullen DR, Harms PW. Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for neuroendocrine carcinoma. Histopathology. 2018 Sep 21; doi: 10.1111/his.13758. [Epub ahead of print] PubMed PMID: 30239030.
126. Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Med Oncol. 2018 Oct 5;35(12):152. doi: 10.1007/s12032-018-1212-6. PubMed PMID: 30291535.
127. Bismar TA, Hegazy S, Feng Z, Yu D, Donnelly B, Palanisamy N, Trock BJ. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. J Cancer Res Clin Oncol. 2018 Nov;144(11):2117-2125. doi: 10.1007/s00432-018-2730-5. Epub 2018 Aug 12. PubMed PMID: 30101374.
128. Chakravarthi BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, Carskadon S, Rao U, Gordetsky J, Manne U, Netto GJ, Sudarshan S, Palanisamy N, Varambally S. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate. 2018 Dec;78(16):1311-1320. doi: 10.1002/pros.23704. Epub 2018 Jul 26. PubMed PMID: 30051493.
129. Bhatia V, Yadav A, Tiwari R, Nigam S, Goel S, Carskadon S, Gupta N, Goel A, Palanisamy N, Ateeq B. Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer. Clin Cancer Res. 2018 Dec 26; doi: 10.1158/1078-0432.CCR-18-3230. [Epub ahead of print] PubMed PMID: 30587549.
130. Madan R, Deebajah M, Alanee S, Gupta NS, Carskadon S, Palanisamy N, Williamson SR. Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria. Histopathology. 2019 Feb 5; doi: 10.1111/his.13833. [Epub ahead of print] PubMed PMID: 30720899.
131. Abou-Ouf H, Ghosh S, Box A, Palanisamy N, Bismar TA. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer. J Cancer Res Clin Oncol. 2019 May 25. doi: 10.1007/s00432-019-02933-z. [Epub ahead of print] PMID:31129769.
132. Friedman BJ, Hernandez S, Fidai C, Jiang A, Shwayder TA, Carskadon S, Andea AA, Harms PW, Chitale D, Palanisamy N. A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel NTRK3-SCAPER gene fusion. J Cutan Pathol. 2019 Aug 22;. doi: 10.1111/cup.13566. [Epub ahead of print] PubMed PMID: 31437301.
133. Chakravarthi BV, Dedigama-Arachchige P, Carskadon S, Sundaram SK, Li J, Wu KH, Chandrashekar DS, Peabody JO, Stricker H, Hwang C, Chitale DA, Williamson SR, Gupta NS, Navone NM, Rogers C, Menon M, Varambally S, Palanisamy N. Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. Neoplasia. 2019 Aug 22;21(10):989-1002. doi: 10.1016/j.neo.2019.07.010. [Epub ahead of print] PubMed PMID: 31446281; PubMed Central PMCID: PMC6713813.
134. Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, Narla G, Den RB, Freedman ML, Brady DC, Asangani IA. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discov. 2019 Nov;9(11):1538-1555. doi: 10.1158/2159-8290.CD-19-0189. Epub 2019 Aug 29. PubMed PMID: 31466944.
135. Jaiswal PK, Koul S, Palanisamy N, Koul HK. Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): a target for cancer therapeutic intervention? Cancer Cell Int. 2019; 19:224. doi: 10.1186/s12935-019-0947-2. eCollection 2019. PubMed PMID: 31496918; PubMed Central PMCID: PMC6717390.
136. Lu Z, Williamson SR, Carskadon S, Arachchige PD, Dhamdhere G, Schultz DS, Stricker H, Peabody JO, Jeong W, Chitale DA, Bismar TA, Rogers CG, Menon M, Gupta NS, Palanisamy N. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue. Prostate. 2019 Oct 4; doi: 10.1002/pros.23914. [Epub ahead of print] PubMed PMID: 31584209.
137. Jebastin JAS, Perry KD, Chitale DA, Mott MP, Sanchez J, Fritchie KJ, Palanisamy N, Williamson SR. Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma With Features Mimicking Spindle Cell Lipoma. Int J Surg Pathol. 2019 Oct 31;1066896919884648. doi: 10.1177/106689691 9884648. [Epub ahead of print] PubMed PMID: 31672072.
138. Chan MP, Plouffe KR, Liu CJ, Palanisamy N, Carskadon S, Zhao L, Nazarian RM, Durham AB, Johnson TM, Andea AA, Patel RM, Lowe L, Fullen DR, Brown NA, Tomlins SA, Udager AM, Harms PW. Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. Mod Pathol. 2019 Dec 19; doi: 10.1038/s41379-019-0424-4. [Epub ahead of print] PubMed PMID: 31857679.
139. Hamzeh O, Alkhateeb A, Zheng JZ, Kandalam S, Leung C, Atikukke G, Cavallo-Medved D, Palanisamy N, Rueda L. A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer. Diagnostics (Basel).2019 Dec 11;9(4). doi: 10.3390/diagnostics9040219. PubMed PMID: 31835700.
140. Zeinali M, Lee M, Nadhan A, Mathur A, Hedman C, Lin E, Harouaka R, Wicha MS, Zhao L, Palanisamy N, Hafner M, Reddy R, Kalemkerian GP, Schneider BJ, Hassan KA, Ramnath N, Nagrath S. High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients. Cancers (Basel). 2020 Jan 3;12(1). doi: 10.3390/cancers12010127. PubMed PMID: 31947893.
141. Tiwari R, Manzar N, Bhatia V, Yadav A, Nengroo MA, Datta D, Carskadon S, Gupta N, Sigouros M, Khani F, Poutanen M, Zoubeidi A, Beltran H, Palanisamy N, Ateeq B. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nat Commun. 2020 Jan 20;11(1):384. doi: 10.1038/s41467-019-14184-0. PubMed PMID: 31959826.
142. Jebastin Thangaiah J, Vickery J, Selwanes W, Al-Haddad E, Perry KD, Palanisamy N, Poulik JM, Williamson SR, Chitale DA, Shehata BM. A Novel COL1A1-CAMTA1 Rearrangement in Cranial Fasciitis. Int J Surg Pathol. 2020 Mar 19;1066896920912485. doi: 10.1177/1066896920912485. [Epub ahead of print] PubMed PMID: 32192385.
143. Dedigama-Arachchige P, Carskadon S, Li J, Loveless I, Alhamar M, Peabody JO, Stricker H, Chitale DA, Rogers CG, Menon M, Gupta NS, Bismar TA, Williamson SR, Palanisamy N. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. Mod Pathol. 2020 Apr 1; doi: 10.1038/s41379-020-0525-0. [Epub ahead of print] PubMed PMID: 32238875. Preprint in bioRxiv doi: https://doi.org/10.1101/818880.
144. Chandrashekar DS, Chakravarthi BVSK, Robinson AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK, Davuluri S, Guru MS, Guru AS, Naik G, Della Manna DL, Acharya KK, Carskadon S, Manne U, Crossman DK, Ferguson JE, Grizzle WE, Palanisamy N, Willey CD, Crowley MR, Netto GJ, Yang ES, Varambally S, Sonpavde G. Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene. 2020 Mar 30; doi: 10.1038/s41388-020-1275-7. [Epub ahead of print] PubMed PMID: 32231273.
145. Abdelsalam RA, Khalifeh I, Box A, Kalantarian M, Ghosh S, Abou-Ouf H, Lotfi T, Shahait M, Palanisamy N, Bismar TA. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication. J Cancer Res Clin Oncol. 2020 Apr 30;. doi: 10.1007/s00432-020-03221-x. [Epub ahead of print] PubMed PMID: 32350606.
146. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam G, Ravoori M, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon S, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis C, Troncoso P, Navone NM. The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin Cancer Res. 2020 Jun 23;. doi: 10.1158/1078-0432.CCR-20-0479. [Epub ahead of print] PubMed PMID: 32576626.
147. Alhamar M, Vladislav T, Smith SC, Gao Y, Cheng L, Favazza LA, Alani AM, Ittmann MM, Riddle ND, Whiteley LJ, Gupta NS, Carskadon S, Gomez-Gelvez JC, Chitale DA, Palanisamy N, Hes O, Trpkov K, Williamson SR. Gene Fusion Characterization of Rare Aggressive Prostate Cancer Variants - Adenosquamous Carcinoma, Pleomorphic Giant Cell Carcinoma, and Sarcomatoid Carcinoma: An Analysis of 19 Cases. Histopathology. 2020 Jul 8;. doi: 10.1111/his.14205. [Epub ahead of print] PubMed PMID: 32639612.
148. Kahali B, Chen Y, Feitosa MF, Bielak LF, O'Connell JR, Musani SK, Hegde Y, Chen Y, Stetson LC, Guo X, Fu YP, Smith AV, Ryan KA, Eiriksdottir G, Cohain AT, Allison M, Bakshi A, Bowden DW, Budoff MJ, Carr JJ, Carskadon S, Chen YI, Correa A, Crudup BF, Du X, Harris TB, Yang J, Kardia SLR, Launer LJ, Liu J, Mosley TH, Norris JM, Terry JG, Palanisamy N, Schadt EE, O'Donnell CJ, Yerges-Armstrong LM, Rotter JI, Wagenknecht LE, Handelman SK, Gudnason V, Province MA, Peyser PA, Halligan B, Palmer ND, Speliotes EK. A noncoding variant near PPP1R3B promotes liver glycogen storage and MetS but protects against myocardial infarction. J Clin Endocrinol Metab. 2020 Nov 24;. doi: 10.1210/clinem/dgaa855. [Epub ahead of print] PubMed PMID: 33231259.
149. Abou-Ouf H, Assem H, Ghosh S, Karnes RJ, Stoletov K, Palanisamy N, Lewis JD, Bismar TA. High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival. Eur Urol Open Sci. 2021 Jan;23:1-8. doi: 10.1016/j.euros.2020.11.005. eCollection 2021 Jan. PubMed PMID: 34337483; PubMed Central PMCID: PMC8317848.
150. Harms K, Zhao L, Johnson B, Wang X, Carskadon S, Palanisamy N, Rhodes DR, Mannan R, Vo J, Choi JE, Chan MP, Fullen DR, Patel RM, Siddiqui J, Ma VT, Hrycaj S, McLean SA, Hughes TM, Bichakjian CK, Tomlins SA, Harms PW. Virus-positive Merkel cell carcinoma is an independent prognostic group with distinct predictive biomarkers. Clin Cancer Res. 2021 Feb 5;. doi: 10.1158/1078-0432.CCR-20-0864. [Epub ahead of print] PubMed PMID: 33547200.
151. Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. Prostate. 2021 May;81(6):357-358. doi: 10.1002/pros.24111. Epub 2021 Mar 8. PubMed PMID: 33683724.
152. Albawardi A, Livingstone J, Almarzooqi S, Palanisamy N, Houlahan KE, Awwad AAA, Abdelsalam RA, Boutros PC, Bismar TA. Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry. Cancers (Basel). 2021 May 14;13(10). doi: 10.3390/cancers13102363. PubMed PMID: 34068856; PubMed Central PMCID: PMC8153627.
153. Walker SR, Abdelsalam R, Ghosh S, Livingstone J, Palanisamy N, Boutros PC, Yip SM, Lees-Miller SP, Bismar TA. Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. Eur Urol Open Sci. 2021 Jul;29:93-101. doi: 10.1016/j.euros.2021.05.004. eCollection 2021 Jul. PubMed PMID: 34337539; PubMed Central PMCID: PMC8317877.
154. Goel S, Bhatia V, Kundu S, Biswas T, Carskadon S, Gupta N, Asim M, Morrissey C, Palanisamy N, Ateeq B. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression. Nat Commun. 2021 Sep 7;12(1):5325. doi: 10.1038/s41467-021-25623-2. PubMed PMID: 34493733.
References: University of Michigan, Department of Pathology: [[1]] Henry Ford Health System: [[2]] Google Scholar citations: [[3]] ORCID ID: [[4]] NCBI Bibliography: [[5]]